Products
Platform
Research
Market
Learn
Partner
Support
IPO

R

Rubicon Research Share Price

650.5
-12.90 (-1.94%)
RUBICON • 20 Jan, 2026 | 12:59 PM
Buywith MTF at 3.33x leverage
The current prices are delayed, login or Open Demat Account for live prices.

Rubicon Research Stock Performance

1W Return-3.93
1Y Return0.00
Today's Low650
Prev. Close663.40
Mkt Cap (Cr.)10,929.54
1M Return-0.79
3Y Return0.00
52-Week High754.8
Open660.00
PE Ratio64.99
6M Return0.00
Today's High660
52-Week Low570.75
Face Value1

Rubicon Research Company background

Founded in: 1999
Managing director: PRATIBHA SUDHIR PILGAONKAR
Rubicon Research Limited was incorporated on May 6, 1999, as a Private Company as Rubicon Consultants Private Limited, with the RoC. Subsequently, the Companys name was changed from Rubicon Consultants Private Limited to Rubicon Research Private Limited to which a fresh Certificate of Incorporation was issued by the RoC dated September 2, 2002. The Companys status got converted from a Private Company to a Public Company, the name was changed from Rubicon Research Private Limited to Rubicon Research Limited. A fresh Certificate of Incorporation dated July 23, 2024 was issued by the Central Processing Centre, Manesar, Haryana. Rubicon Research is an integrated pharmaceutical company with business encompassing the entire value chain in the research, development and production of pharmaceutical products. The Company is driven by innovation through focused research and development, with an increasing portfolio of specialty products and drugdevice combination products targeting regulated markets, particularly, the United States. It has obtained its GMP manufacturing facilities at Ambernath and Satara in Maharashtra.The Company commenced manufacturing of certain special drugs in Ambernath Manufacturing Facility in 2011. In 2016, the Company acquired majority stake by ECP III Pte Ltd. Further, it acquired majority stake by General Atlantic Singapore RR Pte. Ltd., from ECP III Pte. Ltd. in 2019. In 2021, the Company acquired the business of Meditab Specialities Limited on slump sale as a going concern. In FY 2024, the Company acquired Validus, a New Jersey headquartered marketer of brand name formulation products in the US. It commenced the manufacturing of nasal products at Ambernath Plant in 2024. The Company has acquired Pithampur Manufacturing Facility from Alkem Laboratories Ltd in 2025. The Company came up with its initial public offering of 28,405,841 equity shares of face value of Re 1 each, by raising funds aggregating to Rs 1378 crores, comprising a fresh issue of 10,313,058 equity shares aggregating to Rs 500 crores and the offer for sale of 18,092,783 equity shares aggregating to Rs 878 crores on October 13, 2025.

Rubicon Research Financial Highlights


For the full year FY2025–2026, revenue reached ₹1296.22 crore and profit touched at ₹134.36 crore.

Rubicon Research Share Price Today


As of 20 Jan 2026, Rubicon Research share price is ₹650.5. The stock opened at ₹660 and had closed at ₹663.4 the previous day. During today’s trading session, Rubicon Research share price moved between ₹650.00 and ₹660.00, with an average price for the day of ₹655.00. Over the last 52 weeks, the stock has recorded a low of ₹570.75 and a high of ₹754.80. In terms of performance, Rubicon Research share price has increased by 34.1% over the past six months and has increased by 7.55% over the last year.
Read More
View details of Market Depth

Rubicon Research Fundamental

Market Cap (in crs)

10,929.54

Face Value

1

Turnover (in lacs)

233.97

Key Metrics

Qtr Change %
5.1
Dividend yield 1yr %
0

Rubicon Research Key Financials

View more
Loading chart...
Rubicon Research Quarterly Revenue
Rubicon Research Yearly Revenue
Rubicon Research Quarterly Net Profit/Loss
Rubicon Research Yearly Net Profit/Loss

Rubicon Research Result Highlights

  • Rubicon Research Ltd reported a 15.6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a - of -.

  • Its expenses for the quarter were up by 14.7% QoQ and - - YoY.

  • The net profit increased 24.4% QoQ and - - YoY.

  • The earnings per share (EPS) of Rubicon Research Ltd stood at 3.47 during Q2 FY 2025-26.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Rubicon Research Technical Analysis

Moving Averages Analysis
650.5
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
11
Day EMA5
671.20
Day EMA10
671.20
Day EMA12
670.80
Day EMA20
667.90
Day EMA26
665.00
Day EMA50
656.10
EMA
EMA
Delivery & Volume
Loading chart...

Day

53.60%

Week

57.10%

Month

48.30%

Delivery & Volume

664.98
Pivot
Resistance
First Resistance
677.97
Second Resistance
692.53
Third Resistance
705.52
Support
First Support
650.42
Second support
637.43
Third Support
622.87
Relative Strength Index
49.29
Money Flow Index
49.29
MACD
5.70
MACD Signal
7.01
Average True Range
28.12
Average Directional Index
14.41
Rate of Change (21)
5.24
Rate of Change (125)
0.00
Compare

Rubicon Research Latest News

14 JAN 2026 | Wednesday
13 JAN 2026 | Tuesday
09 JAN 2026 | Friday

Please be aware that Rubicon Research stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account